News Releases Keyword Search Year None20212020201920182017201620152014 Oct 07, 2021 Rocket Pharmaceuticals to Present at the 2021 Cell & Gene Meeting on the Mesa Sep 30, 2021 Rocket Pharmaceuticals to Participate in the Chardan Virtual 5th Annual Genetic Medicines Conference Sep 14, 2021 Rocket Pharmaceuticals Presents Clinical Data from RP-A501 Trial in Danon Disease at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2021 Sep 10, 2021 Rocket Pharmaceuticals Announces Upcoming Danon Disease Presentation at the Heart Failure Society of America Annual Scientific Meeting 2021 Sep 07, 2021 Rocket Pharmaceuticals Appoints Isabel Carmona, J.D., as Chief Human Resources Officer Aug 30, 2021 Rocket Pharmaceuticals Announces $26.4 Million Private Placement Aug 16, 2021 Rocket Pharmaceuticals Announces FDA Lifts Clinical Hold on Danon Disease Trial of RP-A501 Aug 09, 2021 Rocket Pharmaceuticals Reports Second Quarter 2021 Financial Results and Highlights Recent Progress Aug 03, 2021 Rocket Pharmaceuticals to Host Conference Call on Aug. 9 at 4:30 p.m. ET to Discuss Second Quarter Results and Recent Business Highlights May 13, 2021 Rocket Pharmaceuticals Presents Positive Clinical Data from Fanconi Anemia, Leukocyte Adhesion Deficiency-I, and Pyruvate Kinase Deficiency Programs at 24th Annual Meeting of the American Society of Gene and Cell Therapy May 10, 2021 Rocket Pharmaceuticals Reports First Quarter 2021 Financial Results and Highlights Recent Progress Apr 27, 2021 Rocket Pharmaceuticals Announces Upcoming Clinical Data Presentations at the 24th Annual Meeting of the American Society of Gene and Cell Therapy Apr 14, 2021 Rocket Pharmaceuticals Reports Positive Long-Term Clinical Data from RP-L201 Trial for the Treatment of Leukocyte Adhesion Deficiency-I at the Clinical Immunology Society 2021 Annual Meeting Mar 29, 2021 Rocket Pharmaceuticals Receives EMA Priority Medicines (PRIME) Designation for RP-L201 Gene Therapy for Treatment of Leukocyte Adhesion Deficiency-I Mar 22, 2021 Rocket Pharmaceuticals Announces Updated Positive Preliminary Clinical Data from Phase 1 Trial of RP-L301 for the Treatment of Pyruvate Kinase Deficiency Mar 09, 2021 Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy Designation for RP-L201 Gene Therapy for Leukocyte Adhesion Deficiency-I Feb 25, 2021 Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial and Operational Results Feb 18, 2021 Rocket Pharmaceuticals Announces Participation at Upcoming Conferences Jan 11, 2021 Rocket Pharmaceuticals Announces Buildout of R&D and Manufacturing Facility to Support Development of Innovative Gene Therapy Pipeline Jan 06, 2021 Rocket Pharmaceuticals Announces Participation at the 39th Annual J.P. Morgan Healthcare Conference Print Page RSS E-mail Alerts Contact
Keyword Search Year None20212020201920182017201620152014 Oct 07, 2021 Rocket Pharmaceuticals to Present at the 2021 Cell & Gene Meeting on the Mesa Sep 30, 2021 Rocket Pharmaceuticals to Participate in the Chardan Virtual 5th Annual Genetic Medicines Conference Sep 14, 2021 Rocket Pharmaceuticals Presents Clinical Data from RP-A501 Trial in Danon Disease at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2021 Sep 10, 2021 Rocket Pharmaceuticals Announces Upcoming Danon Disease Presentation at the Heart Failure Society of America Annual Scientific Meeting 2021 Sep 07, 2021 Rocket Pharmaceuticals Appoints Isabel Carmona, J.D., as Chief Human Resources Officer Aug 30, 2021 Rocket Pharmaceuticals Announces $26.4 Million Private Placement Aug 16, 2021 Rocket Pharmaceuticals Announces FDA Lifts Clinical Hold on Danon Disease Trial of RP-A501 Aug 09, 2021 Rocket Pharmaceuticals Reports Second Quarter 2021 Financial Results and Highlights Recent Progress Aug 03, 2021 Rocket Pharmaceuticals to Host Conference Call on Aug. 9 at 4:30 p.m. ET to Discuss Second Quarter Results and Recent Business Highlights May 13, 2021 Rocket Pharmaceuticals Presents Positive Clinical Data from Fanconi Anemia, Leukocyte Adhesion Deficiency-I, and Pyruvate Kinase Deficiency Programs at 24th Annual Meeting of the American Society of Gene and Cell Therapy May 10, 2021 Rocket Pharmaceuticals Reports First Quarter 2021 Financial Results and Highlights Recent Progress Apr 27, 2021 Rocket Pharmaceuticals Announces Upcoming Clinical Data Presentations at the 24th Annual Meeting of the American Society of Gene and Cell Therapy Apr 14, 2021 Rocket Pharmaceuticals Reports Positive Long-Term Clinical Data from RP-L201 Trial for the Treatment of Leukocyte Adhesion Deficiency-I at the Clinical Immunology Society 2021 Annual Meeting Mar 29, 2021 Rocket Pharmaceuticals Receives EMA Priority Medicines (PRIME) Designation for RP-L201 Gene Therapy for Treatment of Leukocyte Adhesion Deficiency-I Mar 22, 2021 Rocket Pharmaceuticals Announces Updated Positive Preliminary Clinical Data from Phase 1 Trial of RP-L301 for the Treatment of Pyruvate Kinase Deficiency Mar 09, 2021 Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy Designation for RP-L201 Gene Therapy for Leukocyte Adhesion Deficiency-I Feb 25, 2021 Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial and Operational Results Feb 18, 2021 Rocket Pharmaceuticals Announces Participation at Upcoming Conferences Jan 11, 2021 Rocket Pharmaceuticals Announces Buildout of R&D and Manufacturing Facility to Support Development of Innovative Gene Therapy Pipeline Jan 06, 2021 Rocket Pharmaceuticals Announces Participation at the 39th Annual J.P. Morgan Healthcare Conference
Sep 30, 2021 Rocket Pharmaceuticals to Participate in the Chardan Virtual 5th Annual Genetic Medicines Conference
Sep 14, 2021 Rocket Pharmaceuticals Presents Clinical Data from RP-A501 Trial in Danon Disease at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2021
Sep 10, 2021 Rocket Pharmaceuticals Announces Upcoming Danon Disease Presentation at the Heart Failure Society of America Annual Scientific Meeting 2021
Aug 16, 2021 Rocket Pharmaceuticals Announces FDA Lifts Clinical Hold on Danon Disease Trial of RP-A501
Aug 09, 2021 Rocket Pharmaceuticals Reports Second Quarter 2021 Financial Results and Highlights Recent Progress
Aug 03, 2021 Rocket Pharmaceuticals to Host Conference Call on Aug. 9 at 4:30 p.m. ET to Discuss Second Quarter Results and Recent Business Highlights
May 13, 2021 Rocket Pharmaceuticals Presents Positive Clinical Data from Fanconi Anemia, Leukocyte Adhesion Deficiency-I, and Pyruvate Kinase Deficiency Programs at 24th Annual Meeting of the American Society of Gene and Cell Therapy
May 10, 2021 Rocket Pharmaceuticals Reports First Quarter 2021 Financial Results and Highlights Recent Progress
Apr 27, 2021 Rocket Pharmaceuticals Announces Upcoming Clinical Data Presentations at the 24th Annual Meeting of the American Society of Gene and Cell Therapy
Apr 14, 2021 Rocket Pharmaceuticals Reports Positive Long-Term Clinical Data from RP-L201 Trial for the Treatment of Leukocyte Adhesion Deficiency-I at the Clinical Immunology Society 2021 Annual Meeting
Mar 29, 2021 Rocket Pharmaceuticals Receives EMA Priority Medicines (PRIME) Designation for RP-L201 Gene Therapy for Treatment of Leukocyte Adhesion Deficiency-I
Mar 22, 2021 Rocket Pharmaceuticals Announces Updated Positive Preliminary Clinical Data from Phase 1 Trial of RP-L301 for the Treatment of Pyruvate Kinase Deficiency
Mar 09, 2021 Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy Designation for RP-L201 Gene Therapy for Leukocyte Adhesion Deficiency-I
Feb 25, 2021 Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial and Operational Results
Jan 11, 2021 Rocket Pharmaceuticals Announces Buildout of R&D and Manufacturing Facility to Support Development of Innovative Gene Therapy Pipeline
Jan 06, 2021 Rocket Pharmaceuticals Announces Participation at the 39th Annual J.P. Morgan Healthcare Conference
